ClinicalTrials.gg
CompletedNCT06384547STRIVEUpdated Aug 13, 2026Results posted

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

A Phase 3 interventional study of Veligrotug in Thyroid Eye Disease, sponsored by Viridian Therapeutics, Inc.. Completed at 50 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Viridian Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Enrollment
3rd of 47
231 · median 84
Started
2024
with 10 others
Phase 3
21 of 53
3 open now
Registered
34th of 53
by date
Lead sponsor
9 of 53
Viridian Therapeutics, Inc.

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 3rd largest by enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2024, is one of 21 in phase 3, and was the 34th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with TED. The primary objective of this clinical trial is to evaluate the safety and tolerability of VRDN-001 in participants with TED.

03

Conditions studied

  • Thyroid Eye Disease

Keywords

  • Thyroid Eye Disease
  • Thyroid-Associated Ophthalmopathy
  • Dysthyroid Ophthalmopathy
  • Myopathic Ophthalmopathy
  • Congestive Ophthalmopathy
  • Edematous Ophthalmopathy
  • Infiltrative Ophthalmopathy
  • Thyroid-Associated Orbitopathy
  • Graves Disease
  • Graves Eye Disease
  • Graves Orbitopathy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of TED with or without proptosis and with any clinical activity score (CAS) (0 - 7) and in the opinion of the investigator may benefit from treatment
  • Must agree to use highly effective method as specified in the protocol
  • Female TED participants must have a negative serum pregnancy test at screening
  • Not require immediate ophthalmological or orbital surgery in the study eye for any reason.

Exclusion criteria

Exclusion Criteria:

  • Must not have received prior treatment with another anti-IGF-1R therapy
  • Must not have used systemic , or selenium within 2 weeks prior to Day 1
  • Must not have received rituximab, tocilizumab or other agents within 8 weeks prior to Day 1
  • Must not have received any other therapy for TED within 8 weeks prior to Day 1
  • Must not have received an agent for any condition within 8 weeks prior to the first dose of study medication
  • Must not have a pre-existing ophthalmic condition in the study eye that in the opinion of the Investigator would confound interpretation of the study results
  • Must not have had previous orbital irradiation or decompression surgery involving excision of fat for TED in the study eye's orbit
  • Must not have inflammatory bowel disease
  • Must not have abnormal hearing test before first dose. Must also not have a history of ear conditions considered significant by study doctor.
  • Female TED participants must not be pregnant or lactating.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    Veligrotug 10 mg/kg

    Participants will receive 5 intravenous (IV) infusions of veligrotug 10 milligrams (mg)/kilogram (kg) at 3-week intervals for 12 weeks.

    Drug: Veligrotug

  • Experimental
    Veligrotug 3 mg/kg

    Participants will receive 5 IV infusions of veligrotug 3 mg/kg at 3-week intervals for 12 weeks.

    Drug: Veligrotug

Interventions

  • 5 infusions of veligrotug

    Also known as: VRDN-001

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 15

    An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAE was defined as an AE occurring on or after the day of the first dose of study medication through the end of the study. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline through Week 15

Secondary outcomes

  1. Change From Baseline in Proptosis in the Study Eye as Measured by Exophthalmometer

    Proptosis was defined as distance between the lateral orbital rim and the most anterior position of the cornea in millimeters (mm), measured using an exophthalmometer. Observed change from baseline in proptosis in study eye is reported. Missing data were not imputed.

    Time frame: Baseline, Week 15

  2. Number of Participants With TEAEs Through Week 52

    An AE was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAE was defined as an AE occurring on or after the day of the first dose of study medication through the end of the study. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline through Week 52

07

Results

Posted Aug 13, 2026

Participant flow

As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. The primary and secondary safety analyses and secondary efficacy analysis were measured in the pre-specified study eye per individual participant.

Participant flow — Overall Study
MilestoneVeligrotug 10 mg/kgVeligrotug 3 mg/kg
Started17358
Received at least 1 dose of study drug17358
Completed14146
Not completed3212
Withdrew: Adverse event42
Withdrew: Progressive disease01
Withdrew: Withdrawal by subject145
Withdrew: Failure to adhere to protocol requirements31
Withdrew: Lost to follow-up112
Withdrew: Other than specified01

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 15

An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAE was defined as an AE occurring on or after the day of the first dose of study medication through the end of the study. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Baseline through Week 15
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 15
ParticipantsVeligrotug 10 mg/kgVeligrotug 3 mg/kg
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 1515355
SecondaryChange From Baseline in Proptosis in the Study Eye as Measured by Exophthalmometer

Proptosis was defined as distance between the lateral orbital rim and the most anterior position of the cornea in millimeters (mm), measured using an exophthalmometer. Observed change from baseline in proptosis in study eye is reported. Missing data were not imputed.

Time frame:
Baseline, Week 15
Reported as:
Mean · mm
Change From Baseline in Proptosis in the Study Eye as Measured by Exophthalmometer
mmVeligrotug 10 mg/kgVeligrotug 3 mg/kg
Change From Baseline in Proptosis in the Study Eye as Measured by Exophthalmometer-2.3 ± 1.74-2.1 ± 1.42
SecondaryNumber of Participants With TEAEs Through Week 52

An AE was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAE was defined as an AE occurring on or after the day of the first dose of study medication through the end of the study. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Baseline through Week 52
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Through Week 52
ParticipantsVeligrotug 10 mg/kgVeligrotug 3 mg/kg
Number of Participants With TEAEs Through Week 5215955

Adverse events

Collected over Baseline through Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Veligrotug 10 mg/kg0/173 (0%)10/173 (5.8%)142/173 (82.1%)
Veligrotug 3 mg/kg0/58 (0%)3/58 (5.2%)47/58 (81%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventVeligrotug 10 mg/kgVeligrotug 3 mg/kg
Mesenteric panniculitisGastrointestinal disorders0/1731/58
Amylase increasedInvestigations0/1731/58
Lipase increasedInvestigations0/1731/58
Joint neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1731/58
Cardiac failureCardiac disorders1/1730/58
Graves' diseaseEndocrine disorders1/1730/58
Endocrine ophthalmopathyEye disorders1/1730/58
Optic disc disorderEye disorders1/1730/58
Retinal haemorrhageEye disorders1/1730/58
Retinal tearEye disorders1/1730/58
Most frequent other events
Showing 10 of 22
Most frequent other events
EventVeligrotug 10 mg/kgVeligrotug 3 mg/kg
Muscle spasmsMusculoskeletal and connective tissue disorders77/17317/58
AmenorrhoeaReproductive system and breast disorders23/705/26
FatigueGeneral disorders23/17311/58
HeadacheNervous system disorders30/1735/58
AlopeciaSkin and subcutaneous tissue disorders30/1736/58
DiarrhoeaGastrointestinal disorders19/1739/58
TinnitusEar and labyrinth disorders21/1738/58
Dry skinSkin and subcutaneous tissue disorders23/1735/58
OnychoclasisSkin and subcutaneous tissue disorders21/1736/58
Blood creatine phosphokinase increasedInvestigations18/1735/58

Baseline characteristics

Safety Population included all enrolled participants who received at least 1 IV infusion of study drug.

Age, Continuous
Age, Continuous(years)Veligrotug 10 mg/kgVeligrotug 3 mg/kgTotal
Mean49.1 ± 12.9950.3 ± 12.8949.4 ± 12.95
Sex: Female, Male
Sex: Female, Male(Participants)Veligrotug 10 mg/kgVeligrotug 3 mg/kgTotal
Female13246178
Male411253
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Veligrotug 10 mg/kgVeligrotug 3 mg/kgTotal
Hispanic or Latino311344
Not Hispanic or Latino13238170
Unknown or Not Reported10717
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Veligrotug 10 mg/kgVeligrotug 3 mg/kgTotal
Race — Asian17421
Race — Black or African American16622
Race — White11939158
Race — American Indian or Alaska Native101
Race — Unknown303
Race — Other538
Race — Not Reported8614
Race — Multiple404
08

Study locations

50 sites
  • United Medical Research Institute
    Inglewood, California 90301, United States
  • Advancing Research International, LLC
    Los Angeles, California 90023, United States
  • Stanford Byers Eye Institute
    Palo Alto, California 94303, United States
  • Cockerham Eye Consultants, PC
    San Diego, California 92108, United States
  • FOMAT Medical Research
    Santa Maria, California 93454, United States
  • University of Colorado - Dept of Ophthalmology
    Aurora, Colorado 80045, United States
  • Sina Medical Center LLC
    Homestead, Florida 33034, United States
  • Med-Care Research Inc.
    Miami, Florida 33125, United States
  • Edward Jenner Research Group Center LLC
    Plantation, Florida 33317, United States
  • Sarasota Retina Institute
    Sarasota, Florida 34231, United States
  • Vision Medical Research Inc.
    Orland Park, Illinois 60462, United States
  • University Health Diabetes, Endocrinology & Nephrology Center
    Kansas City, Kansas 64108, United States
  • KU Medical Center, University of Kansas
    Kansas City, Kansas 66103, United States
  • Massachusetts Eye and Ear
    Boston, Massachusetts 02114, United States
  • Ophthalmic Consultants of Boston
    Weymouth, Massachusetts 02189, United States
  • Fraser Eye Care Center
    Fraser, Michigan 48026, United States
  • Kahana Oculoplastic & Orbital Surgery
    Livonia, Michigan 48152, United States
  • University of Minnesota, Department of Ophthalmology and Visual Neurosciences
    Minneapolis, Minnesota 55455, United States
  • Advancing Research International, LLC
    Las Vegas, Nevada 89144, United States
  • Rutgers- New Jersey Medical School- Newark
    Newark, New Jersey 07103, United States
  • New York Eye Ear Infirmary of Mount Sinai
    New York, New York 10003, United States
  • Baylor College of Medicine (BCM) - Ophthalmology
    Houston, Texas 77030, United States
  • Neuro-Eye Clinical Trials
    Houston, Texas 77074, United States
  • Neuro-Ophthalmology of Texas, PLLC
    Houston, Texas 77074, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • West Virginia University Eye Institute
    Morgantown, West Virginia 26506, United States
  • Sydney Eye Hospital
    Sydney, 2000, Australia
  • North Shore Eye Surgery
    Sydney, 2065, Australia
  • CHU d'Angers
    Angers, 49100, France
  • Centre Hospitalier National D'ophtalmologie
    Des Quinze Vingts Paris, 75012, France
  • CH Nice
    Nice, 06000, France
  • AP-HP - Hôpital de la Pitié Salpétrière
    Paris, 75013, France
  • Universitätsmedizin Göttingen
    Göttingen, 37075, Germany
  • Johannes Gutenberg-University Medical Center
    Mainz, 55131, Germany
  • NZOZ E-Vita
    Bialystok, 15-879, Poland
  • Specjalistyczny Osrodek Okulistyczny Oculomedica
    Bydgoszcz, 85-870, Poland
  • Santa Familia PTG Lodz
    Lódz, 90-302, Poland
  • Panstwowy Instytut Medyczny MSWiA
    Warsaw, 02-507, Poland
  • 4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ
    Wroclaw, 53-114, Poland
  • Clinica Bonanova de Cirugia Ocular
    Barcelona, 08022, Spain
  • Hospital Arruzafa
    Córdoba, 14012, Spain
  • Clínica Universidad de Navarra
    Madrid, 28027, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Clinica Universidad de Navarra
    Pamplona, 31008, Spain
  • Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo
    Santiago de Compostela, A Coruña, 15706, Spain
  • Hospital Universitario Virgen De La Macarena, Servicio de Oftalmología
    Seville, 41071, Spain
  • Miguel Servet University Hospital, Clinical Trials Unit
    Zaragoza, 50009, Spain
  • Northwick Park Hospital
    London, HA1 3UJ, United Kingdom
  • Western Eye Hospital, Imperial College NHS Trust
    London, NW1 5QH, United Kingdom
  • Guy's and St. Thomas NHS Trust
    London, SE1 7EH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in May 2025, 11 months.

Results were first posted in Aug 2026, 1 year 3 months after primary completion. A results delay was requested in Apr 2026.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
May 23, 2024
Primary completionActual
May 1, 2025
CompletionActual
Jan 19, 2026
Results delay requested
Apr 24, 2026
Results first posted
Aug 13, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06384547
Lead sponsor
Viridian Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
May 23, 2024
Primary completion
May 1, 2025
Completion
Jan 19, 2026
Results posted
Aug 13, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AVE1642

Start the discussion